AM
NVO

Atwater Malick’s Novo Nordisk NVO Stock Holding History

Atwater Malick’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76M Sell
57,670
-4,699
-8% -$202K 0.6% 31
2026
Q1 		$2.29M Sell
62,369
-2,517
-4% -$119K 0.62% 30
2025
Q4 		$3.3M Sell
64,886
-6,561
-9% -$336K 0.91% 25
2025
Q3 		$3.96M Sell
71,447
-94,158
-57% -$5.51M 1.15% 24
2025
Q2 		$11.4M Buy
165,605
+1,736
+1% +$118K 3.62% 11
2025
Q1 		$11.4M Buy
163,869
+1,641
+1% +$136K 3.85% 10
2024
Q4 		$14M Sell
162,228
-4,604
-3% -$498K 4.68% 7
2024
Q3 		$19.9M Sell
166,832
-1,668
-1% -$222K 6.39% 2
2024
Q2 		$24.1M Sell
168,500
-144
-0.1% -$19.1K 8.29% 1
2024
Q1 		$21.7M Sell
168,644
-1,634
-1% -$195K 7.63% 1
2023
Q4 		$17.6M Sell
170,278
-2,314
-1% -$229K 6.9% 2
2023
Q3 		$15.7M Sell
172,592
-2,760
-2% -$243K 6.91% 2
2023
Q2 		$14.2M Buy
175,352
+70
+0% +$5.72K 6.06% 2
2023
Q1 		$13.9M Sell
175,282
-3,270
-2% -$232K 6.54% 2
2022
Q4 		$12.1M Sell
178,552
-538
-0.3% -$31.5K 5.95% 2
2022
Q3 		$8.92M Buy
179,090
+1,396
+0.8% +$74.8K 4.98% 3
2022
Q2 		$9.9M Buy
177,694
+1,410
+0.8% +$78.2K 5.21% 2
2022
Q1 		$9.79M Buy
176,284
+4,888
+3% +$251K 4.73% 4
2021
Q4 		$9.6M Sell
171,396
-1,652
-1% -$89.5K 4.46% 5
2021
Q3 		$8.31M Buy
173,048
+2,134
+1% +$103K 4.39% 5
2021
Q2 		$7.16M Buy
170,914
+7,912
+5% +$307K 3.96% 9
2021
Q1 		$5.5M Sell
163,002
-7,256
-4% -$258K 3.37% 14
2020
Q4 		$5.95M Buy
170,258
+2,762
+2% +$95.5K 3.74% 11
2020
Q3 		$5.82M Buy
167,496
+3,434
+2% +$114K 4.07% 8
2020
Q2 		$5.37M Buy
164,062
+2,670
+2% +$85.2K 4.23% 7
2020
Q1 		$4.86M Buy
161,392
+2,694
+2% +$80.2K 4.66% 7
2019
Q4 		$4.59M Buy
158,698
+5,854
+4% +$162K 3.65% 15
2019
Q3 		$3.95M Buy
152,844
+7,508
+5% +$190K 3.32% 18
2019
Q2 		$3.71M Buy
145,336
+6,102
+4% +$151K 3.4% 18
2019
Q1 		$3.64M Buy
139,234
+5,418
+4% +$133K 3.56% 17
2018
Q4 		$3.08M Buy
+133,816
New +$2.97M 3.45% 16

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Atwater Malick's NVO Position: Q2 2026 in Review

Atwater Malick reduced its Novo Nordisk (NVO) stake by 7.5% in Q2 2026, selling an estimated $202K and leaving 57,670 shares worth $2.76M. The position accounts for 0.6% of the portfolio, ranked #31.

Atwater Malick first reported a position in NVO in Q4 2018 and has held it in 31 quarters since. The position peaked at $24.1M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Atwater Malick held 57,670 shares of Novo Nordisk worth $2.76M as of Q2 2026.
  • Atwater Malick sold 4,699 Novo Nordisk shares in Q2 2026, an estimated $202K.
  • Novo Nordisk made up 0.6% of Atwater Malick's portfolio in Q2 2026, its #31 holding.
  • Atwater Malick first reported a position in Novo Nordisk in Q4 2018 and has held it in 31 quarters since.
  • Atwater Malick's Novo Nordisk position peaked at $24.1M in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Atwater Malick's 13F filing for Q2 2026, filed 27 Jul 2026.